JSKN-027

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameJSKN-027

Drug Alias NameJSKN-027JSKN027

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-Vascular endothelial growth factor receptor 2DNA topoisomerase I inhibitors

TargetsProgrammed death-ligand 1Vascular endothelial growth factor receptor 2DNA topoisomerase I

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAlphamab Oncology

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Alphamab Biopharmaceuticals Co Ltd

Inactive CompaniesAlphamab Oncology

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A